Catawba Capital Management Va buys $3,500,803 stake in Baxter International Inc (BAX)

Baxter International Inc (BAX) : Catawba Capital Management Va scooped up 1,200 additional shares in Baxter International Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 72,256 shares of Baxter International Inc which is valued at $3,500,803.Baxter International Inc makes up approximately 0.84% of Catawba Capital Management Va’s portfolio.

Other Hedge Funds, Including , Nadler Financial Group reduced its stake in BAX by selling 149 shares or 3.0% in the most recent quarter. The Hedge Fund company now holds 4,810 shares of BAX which is valued at $233,045. Baxter International Inc makes up approx 0.09% of Nadler Financial Group’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in BAX by selling 2,223,042 shares or 97.46% in the most recent quarter. The Hedge Fund company now holds 57,988 shares of BAX which is valued at $2,778,785. Baxter International Inc makes up approx 0.01% of Bnp Paribas Arbitrage Sa’s portfolio.Washington Trust Bank boosted its stake in BAX in the latest quarter, The investment management firm added 56 additional shares and now holds a total of 285 shares of Baxter International Inc which is valued at $13,657.

Baxter International Inc opened for trading at $48.37 and hit $48.55 on the upside on Friday, eventually ending the session at $48.45, with a gain of 0.48% or 0.23 points. The heightened volatility saw the trading volume jump to 35,83,251 shares. Company has a market cap of $26,351 M.

On the company’s financial health, Baxter International Inc reported $0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.40. The company had revenue of $2585.00 million for the quarter, compared to analysts expectations of $2516.16 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.

Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Jul 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 50 from a previous price target of $47 .

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Leave a Reply

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.